IBA Announces Contract with Moffitt Cancer Center for a Proteus ONE Proton Therapy Solution

February 7, 2023 — IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology, today announces that it has received the downpayment for a contract signed at the end of December 2022 with the H. Lee Moffitt Cancer Center and Research Institute Hospital (“Moffitt”) in Tampa, Fla., for the installation of its Proteus ONE compact proton therapy system. As Florida’s only National Cancer Institute-designated comprehensive cancer center, Moffitt previously announced this new proton therapy treatment facility as part of its ongoing expansion. 

IBA’s Proteus ONE, as the only user-centric compact Imaged Guided Intensity Modulated Proton Therapy solution, includes Cone Beam Computed Tomography (CBCT) and an open gantry solution with surface-guided proton therapy capabilities enabling high-quality treatments with optimized patient throughput and excellent user and patient experience. The contract with Moffitt includes a 10-year operation and maintenance agreement, and it is expected that patients will start being treated in 2026. 

The typical end-user price for a Proteus ONE system with a 10-year maintenance contract ranges between 40-50 million US dollars. Revenue recognition on the contract started in 2022. 

Olivier Legrain, Chief Executive Officer of IBA, commented: “This new contract bolsters IBA’s market-leading position in the US and globally, marking IBA’s ninth Proteus®ONE in the region and 40th Proteus ONE worldwide. As an NCI-designated comprehensive cancer center, Moffitt is renowned for scientific excellence and innovative research, and we look forward to working with them to deliver world-class cancer care to patients. With another high-quality contract secured, an active global pipeline and an all-time record order intake in 2022, IBA has entered 2023 in a position of confidence.”     

Patrick Hwu, Chief Executive Officer of Moffitt Cancer Center, said: “Our sole mission at Moffitt is to contribute to the prevention and cure of cancer. Proton therapy is a revolutionary and innovative tool to help us accomplish this mission for our patients and their loved ones. As the global market leader, IBA was the clear choice to partner with us as we continue innovating with this exciting treatment.” 

For more information: www.iba-worldwide.com